… When it comes to developing new Parkinson's treatments, it's crucial to … including The Michael J. Fox Foundation (MJFF), to learn how to incorporate patient needs and priorities into … diverse self-reported data is critically important," says incoming Fox Insight Principal Investigator Carlie Tanner, MD, …

… for Clinical Development Supplement Promising Outcomes of Original Grant: A newly developed glyoxylate series of metalloporphyrin compounds designed to penetrate the blood brain barrier have shown high potencies as antioxidants. A recent NADD award … Novel Approaches to Drug Discovery …

… no biomarkers available for use as a reliable diagnostic test. We find pathological aggregates of alpha-synuclein, … structures in the blood. In this study, we will work to establish a reliable test for this biomarker. The ability to differentiate people with PD from healthy individuals—and …

… Join The Michael J. Fox Foundation’s mission to discover better treatments and, ultimately, a cure for … of the disease.  Explore the links to find out how you can get involved in each study, and please share … The study is enrolling people ages 30+ with PD motor complications and on current Levodopa medications. Read more …

… (PD) mutations in the LRRK2 protein have been linked to decreased GTPase (enzyme that binds to G proteins) … To develop new therapeutic strategies, we will investigate how different types of LRRK2 sites interact and regulate … will help accelerate development of the most promising compounds identified. …

… The sudden inability to move while walking, or feeling like your feet are stuck … goes for cognitive (memory and thinking) problems: They may come on to varied degrees at any time in the course of PD, … in parts of the brain that control movement and cognition showed immediate improvements on tests of walking and …